Skip to content

UroGen Pharma Ltd

US · URGN #2773 by market cap Listed 2017
27.65 -4.08 -12.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 31.40 -1.04%
After-hours 27.65 0.00%
Overnight 31.56 -0.54%
50.2924.7527.652026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on URGN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -14.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 10.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation B-

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 10.1x Better than 79%
Price / Sales 5.1x Better than 22%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 88.7% Better than 96%
Operating margin -113.7% Better than 7%
Net margin -139.8% Better than 6%
Return on equity -211.6% Better than 3%
Return on invested capital -208.3% Better than 1%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -41.0% Better than 10%
6-month return -4.3% Better than 48%
12-month return (ex latest month) 33.3% Better than 72%
Distance below 52-week high 45.6% Better than 23%
Financial Health D+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.0x Better than 81%
Debt to assets 64.0% Better than 7%
Interest coverage -9.0x Better than 14%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 125.0% Better than 88%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +5.61%
1M -21.02%
3M -40.92%
6M -8.50%
YTD +18.06%
1Y +11.31%
3Y +122.45%
5Y +129.27%

Key statistics

Price & volume

Prev close
31.73
Open
31.15
Day range
27.57 - 31.90
Avg price
29.63
Volume
2.40M
Turnover
71.09M
Amplitude
13.65%
52-week range
16.50 - 50.81

Valuation

P/E
-8.67
P/E (TTM)
-21.11
P/B
-10.83
EPS
-3.19
Net profit
-156.46M
Net assets
-125.22M

Share structure

Market cap
1.36B
Float cap
1.20B
Shares out
49.05M
Float shares
43.57M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2017-05-04
52-week range 32% of range
16.50 50.81

45.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.72M net over the window

Short interest

Shares short
5.11M
As of
2026-10-30

Frequently asked questions

What is the current stock price of UroGen Pharma Ltd (URGN)?

UroGen Pharma Ltd last traded at 27.65. This page shows a periodic quote snapshot. Check the displayed quote time.

What is UroGen Pharma Ltd's market cap?

About 1.36B.

What is the P/E ratio of UroGen Pharma Ltd?

The trailing twelve-month P/E is -21.11. The Valuation tab shows it against the stock's own five-year range.

Does UroGen Pharma Ltd pay a dividend?

UroGen Pharma Ltd does not currently pay a regular dividend.

Is UroGen Pharma Ltd a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 62.20, which implies 125.0% upside from the current price. This is not investment advice.

What is UroGen Pharma Ltd's StockVane Quant Rating?

The StockVane Momentum strategy currently rates UroGen Pharma Ltd a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

UroGen Pharma Ltd discussion 0 comments

Add a comment